FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W64944024> ?p ?o ?g. }

• W64944024 endingPage "223" @default.
• W64944024 startingPage "205" @default.
• W64944024 abstract "The increasing global prevalence of type 2 diabetes represents a significant burden of disease for afflicted patients and for health care systems. In the developed world poorly controlled diabetes is the leading cause of non-traumatic amputation, blindness and end-stage renal disease requiring dialysis and kidney transplant. Additionally, diabetes represents a significant risk factor for the development of cardiovascular disease with its associated morbidity and premature death. Currently available glucose lowering drugs used to treat type 2 diabetes do not impede progression of the disease. Therefore, as the disease progresses these agents rapidly lose efficacy, first as monotherapy and then in combination, resulting in poorly controlled disease. Clearly, there is a significant need for novel glucose lowering drugs for type 2 diabetes that will deliver sustained efficacy over several years by impeding disease progression. Such agents would reduce the risk of developing the microvascular complications of diabetes that ultimately result in amputation, blindness and kidney transplant. Novel glucose lowering drugs should ideally also exhibit a positive impact on the increased cardiovascular risk associated with diabetes. The incretin-based therapies first entered the market in the mid 2000’s and were heralded for their potential to impede progression of type 2 diabetes and to reduce cardiovascular risk. Through mimicking the actions of the gut incretin hormone GLP-1, these drugs had been shown to lower blood glucose in clinical trials by potentiating glucose stimulated insulin secretion from pancreatic β-cells. Moreover, data from preclinical rodent disease models and isolated human pancreatic islets suggested that these novel agents could preserve pancreatic β-cell function and thus impede disease progression. Further preclinical and clinical data supported the notion that these drugs could also aid blood glucose control by suppressing glucagon secretion, slowing gastric emptying and by suppressing appetite. The incretin-based drugs have potential to reduce cardiovascular risk through their ability to reduce body weight, blood pressure and atherogenic blood lipids. This chapter will review the incretin-based therapies and consider what impact these new drugs have made to date in the pharmacotherapy of type 2 diabetes. The incretin-based therapies are of particular relevance to this book as this class of drugs is composed of two sub-classes, injectable peptide drugs and oral small molecule drugs. The similarities and differences between these small molecule and peptide drugs are described." @default.
• W64944024 created "2016-06-24" @default.
• W64944024 creator A5011350446 @default.
• W64944024 creator A5041750131 @default.
• W64944024 date "2013-01-01" @default.
• W64944024 modified "2023-09-27" @default.
• W64944024 title "Therapies for type 2 diabetes" @default.
• W64944024 cites W2000074754 @default.
• W64944024 cites W2002757015 @default.
• W64944024 cites W2007914298 @default.
• W64944024 cites W2008132861 @default.
• W64944024 cites W2029228033 @default.
• W64944024 cites W2033746319 @default.
• W64944024 cites W2051903648 @default.
• W64944024 cites W2058514432 @default.
• W64944024 cites W2064437324 @default.
• W64944024 cites W2072114549 @default.
• W64944024 cites W2092287139 @default.
• W64944024 cites W2109688740 @default.
• W64944024 cites W2109728760 @default.
• W64944024 cites W2113544353 @default.
• W64944024 cites W2116286254 @default.
• W64944024 cites W2142400535 @default.
• W64944024 cites W2146901298 @default.
• W64944024 cites W2157665742 @default.
• W64944024 cites W2520432709 @default.
• W64944024 doi "https://doi.org/10.1016/b978-0-12-397176-0.00006-6" @default.
• W64944024 hasPublicationYear "2013" @default.
• W64944024 type Work @default.
• W64944024 sameAs 64944024 @default.
• W64944024 citedByCount "2" @default.
• W64944024 countsByYear W649440242015 @default.
• W64944024 countsByYear W649440242016 @default.
• W64944024 crossrefType "book-chapter" @default.
• W64944024 hasAuthorship W64944024A5011350446 @default.
• W64944024 hasAuthorship W64944024A5041750131 @default.
• W64944024 hasConcept C126322002 @default.
• W64944024 hasConcept C134018914 @default.
• W64944024 hasConcept C177713679 @default.
• W64944024 hasConcept C2777180221 @default.
• W64944024 hasConcept C2778653478 @default.
• W64944024 hasConcept C2778881409 @default.
• W64944024 hasConcept C2779134260 @default.
• W64944024 hasConcept C555293320 @default.
• W64944024 hasConcept C60644358 @default.
• W64944024 hasConcept C71924100 @default.
• W64944024 hasConcept C86803240 @default.
• W64944024 hasConceptScore W64944024C126322002 @default.
• W64944024 hasConceptScore W64944024C134018914 @default.
• W64944024 hasConceptScore W64944024C177713679 @default.
• W64944024 hasConceptScore W64944024C2777180221 @default.
• W64944024 hasConceptScore W64944024C2778653478 @default.
• W64944024 hasConceptScore W64944024C2778881409 @default.
• W64944024 hasConceptScore W64944024C2779134260 @default.
• W64944024 hasConceptScore W64944024C555293320 @default.
• W64944024 hasConceptScore W64944024C60644358 @default.
• W64944024 hasConceptScore W64944024C71924100 @default.
• W64944024 hasConceptScore W64944024C86803240 @default.
• W64944024 hasLocation W649440241 @default.
• W64944024 hasOpenAccess W64944024 @default.
• W64944024 hasPrimaryLocation W649440241 @default.
• W64944024 hasRelatedWork W1540807578 @default.
• W64944024 hasRelatedWork W2079980094 @default.
• W64944024 hasRelatedWork W2554424493 @default.
• W64944024 hasRelatedWork W2888428943 @default.
• W64944024 hasRelatedWork W2972066095 @default.
• W64944024 hasRelatedWork W3041563066 @default.
• W64944024 hasRelatedWork W4206822025 @default.
• W64944024 hasRelatedWork W73139627 @default.
• W64944024 hasRelatedWork W1720298151 @default.
• W64944024 hasRelatedWork W1770598794 @default.
• W64944024 isParatext "false" @default.
• W64944024 isRetracted "false" @default.
• W64944024 magId "64944024" @default.
• W64944024 workType "book-chapter" @default.